Fluorescence photography in the evaluation of hyperpigmentation in photodamaged skin.
BACKGROUND
Treatment-related changes in hyperpigmentation are difficult to quantify with visible light photography, especially when the changes are subtle.


OBJECTIVE
Our purpose was to determine the utility and reliability of fluorescence photography to measure changes in mottled and diffuse hyperpigmentation.


METHODS
Thirty-two subjects, with mildly to moderately photodamaged skin, completed a 36-week, double-blind, vehicle-controlled study of tretinoin cream 0.025%. Clinical evaluation of hyperpigmentation as well as standard flash photographs and fluorescence photographs were obtained at baseline and week 36.


RESULTS
The fluorescence photographs were evaluated blindly and yielded macule counts that decreased significantly from baseline in tretinoin-treated subjects compared with vehicle-treated subjects (31% vs 11% decrease; p = 0.02). Diffuse hyperpigmentation, as evaluated from the fluorescence photographs, decreased 16% from baseline for tretinoin-treated subjects and increased 5% for vehicle-treated subjects (p < 0.01). No significant differences in mottled or diffuse hyperpigmentation were observed between groups through clinical evaluation.


CONCLUSIONS
Fluorescence photography is a noninvasive method that is sensitive in the evaluation and quantification of distribution and changes of mottled and diffuse hyperpigmentation.
Kollias
N
N
Department of Dermatology, Massachusetts General Hospital, Boston 02114, USA.
Gillies
R
R
Cohén-Goihman
C
C
Phillips
S B
SB
Muccini
J A
JA
Stiller
M J
MJ
Drake
L A
LA
D000328:Adult; D000368:Aged; D004311:Double-Blind Method; D005069:Evaluation Studies as Topic; D005453:Fluorescence; D006801:Humans; D017495:Hyperpigmentation / Q000188:drug therapy / Q000209:etiology / Q000473:pathology*; D007641:Keratolytic Agents / Q000494:pharmacology / Q000627:therapeutic use; D008875:Middle Aged; D010781:Photography / Q000379:methods*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D015595:Skin Aging / Q000187:drug effects / Q000473:pathology*; D014212:Tretinoin / Q000494:pharmacology / Q000627:therapeutic use
D007641:Keratolytic Agents; D014212:Tretinoin